|
|
|
|
|
|
|
Nymox Pharm Corp (NYMX)
|
|
4.149 -0.031 (-0.74%)
|
04-20 14:38
|
|
Open:
|
4.18
|
Pre. Close:
|
4.18
|
|
High:
|
4.2499
|
Low:
|
4.07
|
|
Volume:
|
98,722
|
Market Cap:
|
237M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
4.305 - 4.328
|
4.328 - 4.347
|
|
Low:
|
4.117 - 4.142
|
4.142 - 4.164
|
|
Close:
|
4.138 - 4.181
|
4.181 - 4.218
|
|
|
|
Technical analysis (as of: 2018-04-20 1:10:56 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a STRONG SELL today, downgraded from higher rating. This stock seems to be very strong for short side. So you may continue to hold the short positions or sell your long positions. You are relatively safe to short or sell as long as the BUY warning is not issued.
|
|
Target:
|
Six months: 5.37 One year: 6.28
|
|
Support:
|
Support1: 3.96  Support2: 3.56
|
|
Resistance:
|
Resistance1:
4.60 Resistance2: 5.37
|
|
Pivot:
|
4.15
|
|
Moving Averages:
|
MA(5): 4.20 MA(20): 4.16
MA(100): 3.58 MA(250): 3.74
|
|
MACD:
|
MACD(12,26):
0.12 Signal(12,26,9): 0.14
|
|
%K %D:
|
%K(14,3): 47.86 %D(3): 50.58
|
|
RSI:
|
RSI(14): 52.79
|
|
52-Week:
|
High: 5.1
Low: 3 Change(%): -11.3
|
|
Average Vol(K):
|
3-Month: 13689
10-Days 8618
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.NYMX has closed above bottom band by 37.0%. Bollinger Bands are 35.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-04-05T06:37:38-04:00
A Shift To Value In The Forensic Algorithm Stock Selections
2018-02-28T13:07:16-05:00
Nymox Pharmaceutical May Have The Best Risk/Reward Profile In Biotech
2018-02-07T08:00:00-05:00
Your Daily Pharma Scoop: Nabriva Pullback, GW Pharmaceuticals Makes Progress, ContraVir Announces Promising Results
2018-02-05T11:27:01-05:00
Nymox to file U.S. marketing application for fexapotide triflutate for BPH
2018-02-01T10:39:37-05:00
The Clock Is Ticking For Nymox Pharma's European Drug Application - Bet On A Rejection
2018-01-24T08:00:00-05:00
Your Daily Pharma Scoop: Progenics Gaining Momentum, Nymox Data, Ligand Outlicenses Platform
2018-01-22T12:45:07-05:00
Midday Gainers / Losers (1/22/2018)
2018-01-22T12:20:29-05:00
Nymox Pharma's fexapotide shows long-term benefit in men with low-grade prostate cancer; shares ahead 20%
|
|
|
Financial Analysis
|
|
Growth
|
NA
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
NA
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
NA
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
